Meta-analysis for association of <i>TCF4</i> SNP rs613872 with FECD case/control status.

<p>Horizontal lines denote the 95% CI for the OR for each G allele at rs613872. The width of the squares indicating estimates of OR is proportional to the sample size in each study.</p

Nominally significant results from association analyses for CCT.

<p>Genes <i>FOXO1, AKAP6</i> and <i>AKAP13</i> showed no significant associations, and therefore do not appear in this table. Position, physical map position (NCBI human genome build 36); Ref. All., reference (minor) allele; effect, expected µm change in CCT per copy of the reference allele (additive model) or for presence of minor allele (dominant model). <i>p</i> values in <i>italics</i> are less than 0.05; in <b>bold,</b> less than 0.001 (the Bonferroni threshold for study-wide significance at the 0.05 level). *, dominant model.</p

Candidate genes for FECD and related diseases of the cornea.

<p>The columns FECD and CCT indicate whether genes have been implicated in Fuchs dystrophy and central corneal thickness, respectively. The effects on CCT are those for rare (variant) alleles; “Increased” and “Decreased” indicate that the variant (minor) allele is associated with an increase or decrease in CCT. A-R syndrome, Axenfeld-Rieger syndrome; PPCD, posterior polymorphous corneal dystrophy; POAG, primary open angle glaucoma; CHED, congenital hereditary endothelial dystrophy; CDPD, corneal dystrophy and perceptive deafness (Harboyan syndrome).</p

Association analyses for FECD case/control status.

<p>Chr., chromosome; No. SNPs, number of SNPs in or near gene passing QC; Best SNP, SNP with smallest <i>p</i> value; Position, physical map position (NCBI human genome build 36); Ref. All., reference (minor) allele; OR, odds ratio per copy of the reference allele (additive model) or for presence of minor allele (dominant model). <i>p</i> values in <i>italics</i> are less than 0.05; in <b>bold,</b> less than 0.001. *, dominant model.</p

Summary of genotyped samples.

<p>Unless otherwise indicated, statistics are shown as mean ± SD.</p>a<p>Total includes 87 individuals with FECD grade of 1–3 in worse eye, not classified as FECD cases or controls.</p>b<p>Average of two eyes, when available.</p

Plot of linkage results for chromosome 2.

<p>−log₁₀(p-value) from the linkage analysis of each trait is plotted against marker location. This plot illustrates that different TB phenotypes were linked to different regions on chromosome 2.</p

Chromosomal regions significant at the α = 0.05 level by trait for analysis of HIV concordantly negative sibling pairs.

<p>cM = centimorgans, Mb = Megabases.</p><p>P-values in boldface indicate results attaining suggestive significance according to Lander-Kruglyak criteria.</p>a<p>cM range indicates locations significant at the nominal α = 0.05 level.</p>b<p>The first column of linkage results for the TNFα phenotype are for pooled p-values, and the second column is for the Phase II data analyzed alone.</p

Plot of linkage results for chromosome 5.

<p>−log₁₀(p-value) from the linkage analysis of each trait is plotted against marker location.</p

Plot of linkage results for chromosome 20.

<p>−log₁₀(p-value) from the linkage analysis of each trait is plotted against marker location.</p

Chromosomal regions significant at the α = 0.05 level by trait.

<p>cM = centimorgans, Mb = Megabases.</p><p>P-values in boldface indicate results attaining suggestive significance according to Lander-Kruglyak criteria.</p>a<p>cM range indicates locations significant at the nominal α = 0.05 level.</p>b<p>The first column of linkage results for the TNFα phenotype are for pooled p-values, and the second column is for the Phase II data analyzed alone.</p